2022 Annual Business Report

Our Financials & Outlook

Financials & Outlook

DEAR SHAREHOLDERS & INVESTORS

The past year allowed us to focus our efforts on two essential objectives: achieving optimal results for our current projects and reshaping Valneva’s path as we approach our tenth year in operation as a specialty vaccine company.

Financials & Outlook

Our Key Figures 2022

The 2022 financial results are marked by the wind-down of our COVID-19 activities and a recovery in the travel market.

 

SHAREHOLDER STRUCTURE (FEBRUARY 2023)

Shareholder structure
Financials & Outlook

Our capital strategy

Our capital strategy is a combination of non-dilutive funding sources and equity capital to finance the development of the Company’s vaccine candidates.

Quote Financials

PETER BÜHLERChief Financial Officer

Financials & Outlook

2023 Outlook

In 2023, Valneva expects further product sales growth as the travel market continues to recover.

 

2022-financial-reports.jpg

Valneva’s financial reports